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Cannabinoid CB2 receptor ligand proﬁling reveals
biased signalling and off-target activity
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The cannabinoid CB2 receptor (CB2R) represents a promising therapeutic target for various
forms of tissue injury and inﬂammatory diseases. Although numerous compounds have been
developed and widely used to target CB2R, their selectivity, molecular mode of action and
pharmacokinetic properties have been poorly characterized. Here we report the most
extensive characterization of the molecular pharmacology of the most widely used CB2R
ligands to date. In a collaborative effort between multiple academic and industry laboratories,
we identify marked differences in the ability of certain agonists to activate distinct signalling
pathways and to cause off-target effects. We reach a consensus that HU910, HU308 and
JWH133 are the recommended selective CB2R agonists to study the role of CB2R in biological
and disease processes. We believe that our unique approach would be highly suitable for the
characterization of other therapeutic targets in drug discovery research.
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T
arget validation is an essential element of pharmacological
research and drug discovery1. Pharmacological
intervention using chemical probes provides a powerful
means to assess the temporal consequences of acute modulation
of protein function under both physiological and pathological
conditions1. High selectivity and well-deﬁned molecular mode
of action of chemical probes are essential to translate the
preclinical studies on non-human species to the patient. This type
of information is, however, often lacking and reproducibility
across different laboratories is sometimes difﬁcult to obtain.
There is a great interest in the development of selective type-2
cannabinoid receptor (CB2R) agonists as potential drug candi-
dates for various pathophysiological conditions2, which include
chronic and inﬂammatory pain3,4, pruritus5, diabetic neuropathy
and nephropathy6,7, liver cirrhosis8, and protective effects
after ischaemic-reperfusion injury9–12. CB2R belongs to the
cannabinoid receptor family of G protein-coupled receptors,
which also includes type-1 cannabinoid receptor (CB1R).
Both CBRs are the biological target of D9-tetrahydrocannabinol
(D9-THC), the main psychoactive component in cannabis13,14.
CB1R and CB2R share an overall homology of 44%, but
the 7-transmembrane spanning region, which contains
the ligand-binding domain, exhibits 68% similarity15. CB2R
is predominantly expressed on immune cells and its expression
level is believed to increase in tissues upon pathological stimuli2,
whereas the CB1R is highly expressed in the brain16. Both
receptors couple to Gi/o proteins and modulate various
intracellular signal transduction pathways, such as inhibition of
cAMP-production, activation of pERK and G protein-coupled
Inward Rectifying Kþ -channels (GIRKs) and recruitment of
b-arrestin to the receptor17–19. It is currently unknown which
signal transduction pathways (or combinations thereof) are
relevant for therapeutic purposes. In addition, some compounds
may act as biased and/or protean agonists18,19, and remarkable
differences between rodent and human receptor orthologues have
been noted, which are complicating the translation of results from
preclinical animal models to human trials.
Different chemical classes have been described as CBR ligands
(for example, mixed CBR agonists: D9-THC (henceforth referred
to as THC), CP55940, WIN55212-2, HU210, and the endo-
genous ligands 2-arachidonoyl glycerol (2-AG) and anandamide
(AEA, N-arachidonoylethanolamine); CB1R antagonists:
SR141716A (rimonabant), and AM251; CB2R agonists: HU308,
HU910, Gp-1a, JWH015, JWH133 and AM1241; and CB2R
antagonists: AM630 and SR144528; see Supplementary Informa-
tion, Supplementary Fig. 1 for structures)2,20. These ligands are
used to explore CBR biology and to obtain preclinical target
validation of the CBR subtypes21. The high homology between
the ligand binding domains of the two receptors and the overall
higher tissue expression of CB1R pose challenges to develop
selective ligands that target only CB2R. Yet, high selectivity is
required to determine the exact role of each receptor in various
(patho)physiological processes and to avoid CB1R-mediated
(psychotropic) side effects caused by THC and other CB1R
ligands. The need for highly selective CB2 ligands is exempliﬁed
by the scientiﬁc dispute whether the CB2R plays an important
role in normal brain function or not. This whole avenue of
research is currently being hampered by possible bias of using
non-selective pharmacological, immunological and genetic tools
and has delayed the development of novel CB2R-based drugs22,23.
Currently, most ligands are only characterized in a binding
assay and/or in a limited set of functional assays using
recombinant human receptors. The results are scattered among
various publications and are derived from different experimental
settings, which may have led to apparent contradictory results23.
Conﬂicting results from in vivo models that employ some of the
above-mentioned ligands have also been described in the
literature (for a review see refs 2,24). Often, information about
potential off-targets and pharmacokinetics of ligands is also
lacking19, which has complicated the comparison and
interpretation of the data and led to confusion about which
are the preferred ligands to be used for in vivo experiments aimed
at validating the CB2 receptor as a therapeutic target.
Unfortunately this situation, which has resulted in a loss of
resources and unnecessary use of animals, is not unique to the
CB2 receptor ﬁeld. The US National Institutes of Health (NIH)
shares these concerns from many scientists about the
reproducibility issues in biomedical research and required
action to counter this problem25. To improve target validation
and to guide the selection of the best ligand for preclinical studies,
a fully detailed proﬁle of the current ‘gold standard’ ligands
is needed.
To provide important guidance for the ﬁeld and to address
potential species-dependent differences, we comprehensively
proﬁled the most widely used CB2R ligands. In several
independent academic and industry laboratories we investigated
receptor binding of both human and mouse CB2R, as well
as multiple signal transduction pathways (GTPgS, cAMP,
b-AR, pERK and GIRK). Selectivity of the ligands was determined
towards a customized panel of proteins associated with
cannabinoid ligand pharmacology, which includes the
CB1R and the major proteins of the endocannabinoid system:
N-acyl ethanolamines biosynthesizing enzyme NAPE-PLD and
AEA hydrolysing enzyme FAAH; 2-AG biosynthesizing enzyme
DAGL and hydrolysing enzymes MAGL, ABHD6 and ABHD12,
as well as towards the putative endocannabinoid transporters;
AEA and 2-AG-binding transient receptor potential (TRP)-
channels (TRPV1–4, TRPM8 and TRPA1) (for a review see
ref. 26). In addition, off-target activity on GPR55, a receptor that
binds CBR-type ligands, and on COX-2, which oxygenates
AEA and 2-AG, was also determined. Determination of the
selectivity of CB2R ligands over these other proteins and
processes involved in the endocannabinoid system, as well as
over the TRP channels (which are involved in similar biological
processes as the CBRs) is essential for the development of
selective CB2R ligands and to avoid complications in the
interpretation of the in vivo results obtained with these
compounds.
To assess which ligands are best suited for in vivo studies, all
18 compounds are proﬁled for their physico-chemical properties,
in vitro absorption distribution metabolism and excretion
(ADME) and pharmacokinetic parameters and cross-reactivity
in the CEREP panel of 64 common off-targets. Commonly used
non-selective ligands, including D9-THC and the endocannabi-
noids 2-AG and anandamide are also tested in vitro. All ligands
are high-quality grade material, provided to each laboratory
by the industry collaborator. The top three candidate CB2R
agonists are further investigated at high doses in vivo to infer
potential interactions with CNS CB1R. All data together results in
the largest data set generated so far under the same experimental
conditions for all cannabinoid receptor ligands, leading to a
consensus that HU910, HU308 and JWH133 possess the best
CB2R agonist proﬁles among the ligands tested on the basis
of selectivity, balanced signalling, pharmacokinetic proﬁle and
off-target activity, and may be considered ‘gold standards’ for
CB2R validation studies in mice.
Results
Physico-chemical properties. The physico-chemical properties
of the 18 compounds tested are listed in Supplementary Table 1
of the Supplementary Information. Molecular weights span
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a range from 312 gmol 1 for JWH133 up to 555 gmol 1
for AM251 and the polar surface area values are overall very low
(8Å for JWH133 up to 63Å for (S)-AM1241), due to a low
number of heteroatoms present in the ligands. Importantly, all
CBR ligands are very lipophilic molecules, which negatively affect
their solubility, ADME-properties and off-target proﬁle. Even the
lowest lipophilicity value (clogP), calculated to be 4.9 for
WIN55212-2, is relatively high. The most lipophilic CBR ligand is
SR144528, which exhibits an extremely high clogP value of
9.2. Consequently, only CP55940 and (rac)-AM1241 were soluble
in an aqueous phosphate buffer system (pH 6.5). Despite the fact
that the membrane permeation coefﬁcient (PAMPA) Peff is low
for several of the molecules, most compounds are expected to
be able to cross biological barriers as high percentages of the
substances were found in membranes.
Afﬁnity and selectivity in CBR binding studies. To determine
the afﬁnity and selectivity of the 18 substances, we performed
[3H]-CP55940 displacement assays using membrane fractions
of CHO cells expressing recombinant human CB2R and CB1R, in
two independent laboratories. In addition, mouse brain and
spleen were used as source of mouse CB1R and CB2R,
respectively.
Using the Pearson correlation analysis, we found a statistically
signiﬁcant correlation between the binding afﬁnities between
the different labs (Pearson coefﬁcient: 0.9304 (hCB1R),
0.6648 (hCB2R) and 0.7720 (mCB2R), see Supplementary
Fig. 2). Figure 1 depicts the selectivity of the ligands for the
CB2R versus CB1R. We found that HU2104CP55940,
WIN55212-24D9-THC were the highest afﬁnity non-selective
human CBR ligands. Conversely, HU308, HU910 and JWH133
were the most selective human CB2R ligands (Supplementary
Table 2), possessing 278-, 166- and 153-fold higher respective
afﬁnities for CB2R than for CB1R. Notably, JWH015 and
Gp-1a were less than 30-fold selective for CB2R. Importantly,
the binding selectivity of the ligands for mouse CB2R over mouse
CB1R appeared to be greatly reduced for all ligands (o100 fold),
except AM630 and SR144528, which are actually more selective
on mCB2R than on hCB2R. The most selective agonists on
mCB2R were (rac)-AM1241 (66-fold), JWH133 (40-fold) and
Gp-1a (20-fold). As expected, AEA and 2-AG, the endogenous
ligands of CB1R and CB2R, were non-selective and showed
moderate binding afﬁnities towards both receptors (pKi B7).
Activity and selectivity of CBR signalling pathways. To deter-
mine the functional activity and selectivity (towards CB2R over
CB1R) of the ligands we performed ﬁve different assays (GTPgS,
cAMP, b-AR, pERK and GIRK) on both human CB2R and
human CB1R (Supplementary Tables 3–7). All ligands were tested
on cAMP signalling on both mouse CBRs and HU910, HU308
and JWH133 were tested on G-protein activation and b-arrestin
recruitment on mCB2R, to determine interspecies behaviour of
the ligands. Efﬁcacy of the ligands is normalized to the effect
produced by CP55940 (10 mM) in all assays; however, it should be
noted that efﬁcacy is relative by deﬁnition, and is dependent on
the reference ligand used as well as the assay conditions.
For both human and mouse CB2R, the potency of the ligands
correlated with their binding afﬁnity in most assays, except for
b-AR and GIRK signalling (Supplementary Fig. 3). Graphs
showing the pEC50 values of the reference ligands for all assays
are shown in Fig. 2a–d.
CP55940 and HU308 behaved as potent full agonists at hCB2R
in the GTPgS assay (Supplementary Table 3), while WIN55212-2
acted as a partial agonist. HU910 behaved as a partial
CB2R agonist as well, but was, together with HU308 and
JWH133, the most selective for CB2R in this assay (185- and
193-fold, respectively). Of note, JWH133 was considered
functionally inactive on hCB1R, because its maximal effect was
only 20% at 10mM. On mCB2R, both HU308 and JWH133 were
full agonists, but HU910 remained partially active. The potency of
all three ligands was similar for human and mouse receptors.
In contrast to previous reports27,28, Gp-1a acted as an inverse
agonist on CB2R, but was inactive at CB1R. Both THC and
the endocannabinoids AEA and 2-AG acted as partial agonists on
both receptors with similar potency.
In the cAMP assay (Supplementary Table 4) all CB2R agonists
displayed higher selectivity (41,000-fold) and higher efﬁcacy,
than in the GTPgS-assay, reﬂecting substantial signal ampliﬁca-
tion in this pathway. Only (rac)-AM1241 remained a partial
agonist in the cAMP assay. Upon comparison of the efﬁcacy
of the ligands between species, in general it appears that many
ligands on the mouse CBRs are partial agonists on cAMP,
in contrast to the human CBRs. This difference in efﬁcacy might
be a result of a difference in CBR expression levels. Differences in
expression levels may also account for the interspecies differences
displayed by (rac)-AM1241, which was previously reported as a
protean agonist (a protean agonist shows differences in signalling
due to differences in experimental conditions, whereas a true
biased agonist has signalling preference due to conformational
changes of the receptor)29. HU910 was found to bind with similar
afﬁnity to both mouse CBRs, but was inactive on mCB1R in
the cAMP assay. HU308, JWH015 and (rac)-AM1241 were the
most selective agonists for hCB2R in this assay, whereas CP55940,
WIN55212-2 and HU210 displayed the highest potency. HU910,
HU308 and JWH133 were the most selective on the mCB2R. Of
note, AEA and 2-AG were relatively weak partial agonists,
especially on human and mouse CB1R (pEC50 o5.2 and Emax
o70%).
All ligands modulated b-AR recruitment (Supplementary
Table 5) to the membrane in CHO cells expressing human
CB2R or CB1R. CP55940 was the most potent ligand in this assay,
followed by WIN55212-2. CP55940 acted as full agonist at
both receptors, but WIN55212-2 displayed partial agonism at
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Figure 1 | CB2R selectivity of cannabinoid reference ligands on mouse
and human CBRs. CB2R selectivity for all cannabinoid receptor reference
ligands are presented as the difference in mean pKi values between CB2R
and CB1R for both the human (black bars) and mouse (white bars)
orthologues. From left to right: ligands with decreasing CB2R selectivity
(from HU308 to Gp-1a), nonselective ligands (from HU210 to CP55940),
ligands with CB1R selectivity (AM251 and SR141716A). pKi values are
obtained from three independent experiments performed in duplicate. Error
bars shown in the ﬁgure represent the s.e. of the mean.
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CB2R, as in the GTPgS assay. The other agonists, including
the ligands JWH133, JWH015, HU308, HU910 (Emax 50–70%)
and the endocannabinoids (Emax 40–80%), only partially
recruited b-AR. The most selective CB2R agonists were HU308,
JWH133 and HU910, which were found to be 282-, 275- and
274-fold more potent for CB2R than CB1R. Of note, JWH133,
HU308 and HU910 were all signiﬁcantly less potent on mCB2R
in b-AR recruitment.
WIN55212-2 was a full agonist in the pERK assay (Suppleme-
ntary Table 6) and demonstrated 86-fold selectivity for the
human CB2R, whereas CP55940 lacked selectivity in this assay.
HU308 and JWH133 were potent and selective CB2R full
agonists, whereas D9-THC and (Rac)-AM1241 acted as partial
agonists on the pERK signalling cascade. Interestingly, HU910,
AEA and 2-AG had low potency in this assay (pEC50o5.5), but
HU910 and 2-AG acted as full agonists at high concentrations.
Most ligands appeared to be less potent and less CB2R-selective
in the GIRK assay (Supplementary Table 7). For example, neither
JWH133 nor THC activated the GIRK pathway at all. JWH015
was the most selective agonist in this assay, followed by HU308.
WIN55212-2 and CP55940 activated the GIRK channels with the
highest potency, but as expected, both were highly potent and
efﬁcacious at CB1R as well.
The high variability in potency and efﬁcacy that the
CB2R agonists displayed across the different signalling pathways
strongly suggests biased signalling. To quantify this ligand bias
towards distinct signal transduction pathways, we performed
operational analysis based on van der Westhuizen et al.
(Supplementary Tables 8–11) (ref. 30). This analysis is based
on the operational model of Black and Leff31, which calculates
signal transduction strength on a given pathway, taking
into account (a) the maximal effect of the system used, (b) the
agonist concentration, (c) the agonist’s maximum efﬁcacy, (d) the
ligand afﬁnity for the receptor and (e) the transducer slope.
In order to eliminate system and observation bias, such as the
level of ampliﬁcation between signalling pathways or assay
sensitivity, we used CP55940 as a reference compound, because it
was the only compound that behaved as a full agonist
with comparable potency in all assays, except for the cAMP
assay. The DDlogR values resulting from this operational analysis
are graphically shown in Fig. 3. The operational analysis on
hCB2R revealed that THC showed statistically signiﬁcant bias
towards pERK signalling compared to b-arrestin and GTPgS.
In addition, THC did not activate GIRK, indicative of high bias
against this pathway. (rac)-AM1241 was biased towards
b-arrestin coupling and pERK signalling compared to GIRK
channel activation. JWH133 was moderately biased towards
b-arrestin compared to GIRK, whereas both WIN55212-2 and
JWH015 showed preference for GIRK compared to cAMP
signalling. AEA showed preference for pERK and GIRK
signalling compared to cAMP, whereas 2-AG was signiﬁcantly
biased towards GIRK compared to G-protein signalling. Upon
comparison between b-AR coupling and cAMP signalling,
all ligands appear to be signiﬁcantly biased. This observation is,
however, confounded by the fact that CP55940, which is used
as the reference ligand, has an exceptionally high potency in
the cAMP assay compared to the other signal transduction
pathways, and might be in fact biased itself towards the cAMP
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pathway. Of note, HU910 and HU308 were well-balanced
ligands without signiﬁcant bias towards any signal transduction
pathway on hCB2R. Of note, HU910, HU308 and JWH133
were signiﬁcantly biased towards G-protein signalling over
b-AR coupling and cAMP signalling on the mCB2R
highlighting a potentially important species difference.
Off-target activity in the endocannabinoid system. To rule out
any indirect effects of the ligands on CB1R and CB2R, we
investigated off-target activity on endocannabinoid-regulating
enzymes, as well as their effects on AEA reuptake inhibition.
None of the ligands showed any off-target activity on a panel of
serine hydrolases, determined in a competitive activity-based
protein proﬁling (ABBP) assay in mouse brain proteome up to
a concentration of 10 mM (Supplementary Fig. 4A). In addition,
none of the ligands showed any signiﬁcant effect at a
concentration of 10 mM when tested on NAPE-PLD, DAGL and
MAGL-overexpressing cells (Supplementary Table 12). The
compounds were also tested on FAAH activity using U937 cell
homogenate at a concentration of 5mM. Only AM251 and Gp-1a
showed partial inhibition of FAAH activity (B30–40%,
Supplementary Fig. 4F).
In addition, none of the agonists had signiﬁcant activity on
ABHD6-, ABHD12- and COX2 activity up to a concentration of
5 mM for COX2 and 10 mM for the ABHDs (Supplementary
Fig. 4B–E). In contrast, the antagonists SR141716A, AM251 and
Gp-1a, which are the structurally most similar ligands in this
panel of ligands, inhibited ABHD12 in the micromolar range with
IC50 values of 6.1, 1.6 and 0.8 mM, respectively (Supplementary
Table 12). AM251 was the only compound of the ligands tested
that had high efﬁcacy on GPR55 in b-arrestin recruitment
(82±9%), albeit with low potency (pEC50¼ 5.49±0.09,
see Supplementary Table 13).
AEA reuptake inhibition was determined in three different
human cell lines: monocyte-like U937 cells, mast cell-like HMC-1
cells and keratinocyte-like HaCaT cells. In U937 and HaCaT cells,
some of the ligands possessed micromolar potency, including
AM251, SR141716A, Gp-1a, HU308 and HU910 (Supplementary
Table 14). In HMC-1 cells, which lack FAAH expression32, all
tested ligands, except SR141716A, were weakly active or inactive
at a concentration of 5mM, which indicates a potential role of
FAAH in the inhibition of AEA uptake in U937 and HaCaT cells.
In agreement with this, the most active AEA reuptake inhibitors
AM251 and Gp-1a partially inhibited FAAH at 5mM in U937 cell
homogenate (Supplementary Fig. 4F). Of note, SR144528 was
inactive up to a concentration of 10 mM in all cell lines, whereas
SR141716A showed FAAH-independent micromolar effects on
AEA reuptake in all cells.
TRP-channels. As AEA and 2-AG activate some TRP channels,
these channels may be regarded as ionotropic cannabinoid
receptors. Here, we tested our ligands on six different TRP
channels (TRPV1–4, TRPA1 and TRPM8). We found that most
TRP channels were activated by one or more ligands, apart from
TRPA1 that was activated by all of them (Supplementary
Table 15). HU308 was the most selective agonist that activated
only TRPV1 and TRPA1 in the high micromolar range, whereas
HU910 activated TRPV3 with submicromolar potency
(0.12±0.05 mM). However, to date, TRPV3-related effects and
toxicity (hypothermia and reduced blood pressure) have not been
observed after in vivo administration of HU910 (ref. 33).
JWH133 only activated TRPA1. Although its efﬁcacy was fairly
high (76.8±3.8% activation), its potency was low (8.5±2.3 mM).
Whereas SR144528 did not target any of the TRP channels,
AM630 was a full agonist at TRPA1 (118±2%). Of note,
SR141716A targeted three out of six TRP channels tested and,
remarkably, nanomolar potency was observed at TRPM8.
Off-target panel (CEREP panel). The CEREP panel served to
screen off-target activity on 64 proteins, which are associated with
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Figure 3 | Heatmap of DDlogR values resulting from the operational analysis. The operational analysis was performed using the procedure described in
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common adverse side effects in humans. JWH133 was identiﬁed
as the most selective ligand with no off-targets detected in
this panel. The summary of all off-targets is shown in Suppleme-
ntary Table 16, in Supplementary Table 20 all CEREP data
are shown. In contrast, CP55940 was the most non-selective
ligand of which we detected 17 off-targets with more than
50% inhibition at 10mM. HU910 and HU308 hit nine and four
off-targets in this panel, respectively. However, of the nine
off-targets of HU910 in this panel only the dopamine uptake
reporter displayed an IC50 of o10mM (IC50¼ 1.40 mM). There-
fore, these off-targets are not likely to be physiologically relevant
at 10 mM. The CB2R-selective antagonist SR144528 had only two
off-targets. Of note, the adenosine A3 receptor was the most
common off-target (Supplementary Table 16). The physiological
relevance of this observation is currently unclear, although it has
previously been published that the endocannabinoid 2-AG has
allosteric activity on this receptor34.
In vitro DMPK and pharmacokinetics. The high overall
lipophilicity (see above) may strongly inﬂuence other ADME
properties. Metabolic stability in human and mouse microsomes
and hepatocytes is low for many of the ligands as indicated by
their high in vitro clearances (Supplementary Table 17). Some
compounds, such as AEA, suffered from high chemical instability
even in dimethylsulfoxide (DMSO) stock solution. For
most ligands, except Gp-1a, microsomal clearances seem to over-
predict the corresponding values in both human and mouse
hepatocytes. The fraction unbound (Fu) was either very low
or not measured for many compounds due to their very high
lipophilicity. None of the molecules is a strong human or mouse
P-gp substrate. In combination with their low polar surface areas,
the ligands are, therefore, likely to reach the brain.
We determined the primary pharmacokinetic parameters
of the compounds (Supplementary Table 18). A mixture
containing 15% DMSO and 85% PEG400 was used as a vehicle
to dissolve the ligands at 1–2mg kg 1 for intravenous (i.v).
administration. In vivo clearances in mice were very high and
span a range from the lowest value of 0.17 l h 1 kg 1 for HU910
up to 6.9 l h 1 kg 1 for (S)-AM1241. The volume of distribution
was high (43 l kg 1) for (S)-AM1241, AM630, Gp-1a and
JWH015, moderate (1–3 l kg 1) for AM251 and JWH133 and
low (o1 l kg 1) for HU910 and SR144528. This resulted in the
longest half-life for HU910 (7 h), whereas JWH133 had a half-
life of only 1 h. As reasonable C0 values, extrapolated from Cmax
values, can be reached for all compounds (see Supplementary
Table 18), the rather short in vivo half-lives raise the possibility
that published mouse in vivo efﬁcacy data using these molecules
might be rather C0 than AUC driven. Future experiments using
accurate concentration/effects relationships might answer this
question.
Following oral administration using aqueous microsuspensions
in rodents, absorption was strongly inﬂuenced by the physico-
chemical properties of the compounds, formulation and feed
conditions of the animals (Supplementary Table 19). HU910 was
suspended in ethanol/cremophor EL/0.9% NaCl (5/5/90% w/w)
whereas HU308 and JWH133 were suspended in an aqueous
gelatine/NaCl vehicle (7.5/0.62% w/w). Maximal plasma concen-
tration peaked B1 h after administration with Cmax ranging
from 201 to 2070 ngml 1. Half-lifes were comparable to
i.v. administration. Bioavailability was not calculated as these
were separate experiments. Taken together these data suggest
a wide variety of application format for in vivo experiments if
care is taken on the formulation aspects. Determination of the
plasma concentrations and pharmacokinetic behaviour seems
however warranted.
In vivo selectivity of HU308 HU910 and JWH133. Finally, to
determine whether the three most selective agonists, HU308,
HU910 and JWH133, elicited cannabimimetic pharmacological
effects in vivo, these compounds were tested in assays highly
sensitive to CB1R activity (catalepsy, antinociception and
hypothermia). HU210, a non-selective, highly potent CB1R/CB2R
agonist was used for comparison. In addition, as binding data
had suggested afﬁnity for mCB1R (pKi¼ 6.14±0.13), HU910
was tested for antagonistic effects in these in vivo measures,
and compared with SR141716A.
As shown in Fig. 4, HU210 dose-dependently elicited catalepsy
(Fig. 4a; F (7,42)¼ 60.7, Po0.0001 (Dunnett’s test); ED50
(95% CL)¼ 0.19 (0.14–0.27) mg kg 1), antinociception
(Fig. 4b; F (7,35)¼ 257.5, Po0.0001 (Dunnett’s test); ED50
(95% CL)¼ 0.41 (0.31–0.54) mg kg 1) and hypothermia (Fig. 4c;
F (7,35)¼ 97.7; Po0.0001 (Dunnett’s test); ED50 (95% CL)¼ 0.35
(0.30–0.41) mg kg 1). In contrast, HU308, HU910 and JWH133
did not produce detectable catalepsy (Fig. 4a), antinociception
(Fig. 4b) or hypothermia (Fig. 4c) within the dose range tested
(1-100mg kg 1).
To test whether HU910 behaves as a CB1 receptor antagonist
in vivo, we tested whether 30mg kg 1 HU910 would antagonize
the pharmacological effects of 1.7mg kg 1 HU210 (that is, an
approximate ED84 dose). Whereas SR141716A (3mg kg 1)
signiﬁcantly antagonized the cataleptic (Fig. 4d; F (1,10)¼ 46.7,
Po0.0001 (Holm-Sidak’s test), antinociceptive (Fig. 4e;
F(1,10)¼ 39.7, Po0.0001 (Holm-Sidak’s test)) and hypothermic
(Fig. 4f; F (1,10)¼ 11.6; Po0.01 (Holm-Sidak’s test)) effects of
HU210, HU910 did not signiﬁcantly reduce the magnitude of
HU210-induced catalepsy (Fig. 4g; P¼ 0.12 (Holm-Sidak’s test)),
antinociception (Fig. 4h; P¼ 0.19 (Holm-Sidak’s test)) or
hypothermia (Fig. 4i; P¼ 0.40 (Holm-Sidak’s test)). These results
indicate that HU308, HU910 and JWH133 lack CB1R activity at
relevant concentrations in vivo.
Discussion
Drug discovery research has focused on the design and synthesis
of selective cannabinoid CB2R agonists. Selective activation of
this receptor has been associated with anti-inﬂammatory and
tissue protective effects without inducing CB1R-mediated
psychoactive side effects. This concept has been supported by
the use of CB2R knock-out mice showing enhanced pathology in
disease models, such as heart, liver or kidney injury and
inﬂammation. It is unclear why two different CB2R agonists
lacked efﬁcacy in phase 2 clinical pain trials35,36, despite
compelling proof-of-concept data obtained in preclinical
studies. This lack of translation not only suggests possible
deﬁciencies in the predicative utility of the preclinical models,
but also that improved understanding of the molecular actions of
CB2R agonists is needed. In addition, selective CB2R ligands
are essential to determine whether CB2R has a physiologically
relevant role in the normal brain function, which is currently
under intense scientiﬁc debate22. To answer this question, a truly
CB2R-selective ligand is needed to avoid confusion caused by
the use of non-selective cannabinoid ligands23.
Here, we have comprehensively characterized a set of 18 CBR
ligands for their physicochemical properties, in vitro molecular
pharmacology, off-target proﬁle and pharmacokinetics to guide
the selection of the optimal ligands to perform preclinical proof-
of-concept studies. An important ﬁnding of our study is that
most agonists display reduced selectivity in binding afﬁnity
and functional efﬁcacy on the mouse CB2R versus CB1R
compared to the human orthologues while the antagonists
display opposite behaviour. This observation may potentially
be explained by the fact that the agonists stabilize different
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13958
6 NATURE COMMUNICATIONS | 8:13958 | DOI: 10.1038/ncomms13958 | www.nature.com/naturecommunications
receptor conformations than antagonists (inverse agonists) by
interacting with different (species speciﬁc) amino acids in the
binding pocket.
The reduced selectivity of the agonists for the mCB2R is a
limitation that needs to be taken into account, especially when
designing studies to investigate (neuro)inﬂammation in mice23.
In contrast to previous reports that classify Gp-1a as a
CB2R agonist27,28, we found Gp-1a to be a functional
CB2R and CB1R antagonist (inverse agonist) in all functional
assays both on human and mouse orthologues.
Another important ﬁnding in the present study is
the provocative evidence indicating biased signalling of
CB2R agonists. For target validation it would be advisable to
use a balanced ligand, instead of a strongly biased agonist, until it
becomes clear that activation of a speciﬁc pathway is desired,
because this may complicate the translation to the human
situation. In our ligand set, THC, 2-AG and (rac)-AM1241
behaved as the most biased agonists on hCB2R, with each
stimulating their most preferred pathway 4100-fold stronger
than their least preferred pathway. Of note, 2-AG and AEA had
distinct proﬁles in signalling pathway activation, which might
open possibilities to explain ligand diversiﬁcation of CBRs37.
Importantly, we found that HU308 and HU910 showed
differences in signalling preference between the human and
mouse CB2R, being well-balanced agonists in all ﬁve signal
transduction pathways on hCB2R, but signiﬁcantly biased on
mCB2R towards G-protein activation compared to b-arrestin
recruitment and cAMP signalling. The consequences of these
interspecies differences in signalling preference for the translation
of preclinical models to the clinic needs to be taken into account
when testing novel drug candidates.
In addition, we found that SR144528 is a very effective
antagonist of CB2R-mediated modulation of cAMP signalling,
but less so on other signal transduction pathways of the same
receptor (GIRK and pERK). This signalling-speciﬁc inhibition
should also be taken into account when studying CB2R agonists
that preferably act through these mechanisms.
To determine off-target activity of the cannabinoid reference
library, we tested them on a customized panel of proteins that
are associated with cannabinoid ligand pharmacology, including
GPR55, proteins involved in the biosynthesis and metabolism
of endocannabinoids (DAGL-a, NAPE-PLD, MAGL, ABHD6,
ABHD12, COX-2, FAAH and endocannabinoid transporter
activity) and the TRP ion channel family. In combination
with the additional off-target data we collected using the CEREP
panel, we found that most ligands displayed a rich poly-
pharmacology (see for a summary of all off-targets per compound
Fig. 5 and Supplementary Table 13). Remarkably, the highly
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Figure 4 | Comparison of in vivo cannabimimetic pharmacological effects. HU210 dose-dependently elicited catalepsy (a), antinociception (b) and
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potent, widely used CBR agonist CP55940 was the least selective
compound at 10mM. Consequently, it would be advisable to
use it only at low concentrations (for example, o100 nM) in
in vitro and in vivo experiments. Furthermore, the fact that
the potent CB1R antagonists AM251 and SR141716A display
CB2R antagonism at low micromolar concentrations should be
taken into account in the experimental design of in vitro-,
and possibly in vivo experiments. Additional off-targets of
CB1R antagonists may further complicate the interpretation of
results. For example, both antagonists, together with Gp-1a, target
ABHD12, an enzyme that hydrolyses 2-AG (ref. 38), and may
therefore increase endogenous 2-AG levels in a cell-selective
manner. The low nanomolar effects of SR141716A on TRPM8
activation should also be kept in mind using cell lines expressing
functional TRPM8. However, this off-target may not be
functionally relevant in vivo because no signiﬁcant effects of
SR141716A on normal temperature regulation have been
reported in rodent or human studies. Finally, AM251
demonstrated also some agonistic activity on GPR55 at high
concentrations.
The CB2R agonists investigated in the present study displayed
diverse physico-chemical properties and pharmacokinetics
(p.o. or i.p. T½ and oral bioavailability), which were far from
optimal and deviate from standard criteria of druglikeness39.
These factors should be taken into account during the design of
in vivo studies. Nevertheless, our PK experiments have proven
that effective drug concentrations can be achieved after
intravenous as well as oral administration. Likely this can also
be achieved using alternative application routes such as food
admix, i.p. and s.c. However, formulations might need to be
optimized for each compound and plasma concentrations need to
be monitored during the course of the in vivo studies. The more
prolonged sustained beneﬁcial effect of HU910 in liver post-
ischaemia paradigms could be explained, at least in part, by its
better pharmacokinetics proﬁle compared to HU308 and
JWH133 (refs 9–11).
Lastly, HU308, HU910 and JWH133 were found to have
no CB1 activity in vivo when tested in the mouse cannabinoid
triad (anti-nociception, catalepsy and hypothermia). The fourth
assay of the mouse cannabinoid tetrad, hypolocomotion, was not
included in this study, because the mice acclimatized to the
locomotor activity chamber due to cumulative dosing procedure.
The omission of the hypolocomotor assay does not confound
our conclusions, because to classify a compound as an in vivo
active CB1 receptor agonist, the ligand must be active in all
four assays. Since HU308, HU910 and JWH133 did not elicit
activity in the ﬁrst three assays, the compounds are not active on
CB1 receptor in vivo. In conclusion, our data from the
18 compounds comprehensively and collectively studied under
controlled experimental conditions indicate that HU910, HU308
and JWH133 are the most suitable CB2R agonists for preclinical
target validation, based on the following observations:
(a) selective agonistic activity on CB2R over CB1R in both
humans and mice, (b) well-balanced activation of signal
transduction pathways on hCB2R, (c) minimal number of
off-target activities at their active concentrations, (d) reasonable
pharmacokinetics and (e) lack of functional in vivo pharmaco-
logical effects indicative of CB1R activity. Of the antagonists
tested, SR144528 is the most suitable for use because of its high
selectivity proﬁle for CB2R in both humans and mice.
On a ﬁnal note, this collaborative effort between multiple
independent academic laboratories and industry to reach
consensus via multicentric proﬁling on the key properties
of widely used CBR ligands in the ever-growing ﬁeld of
(endo)cannabinoid research provides substantial knowledge on
CB2 receptor pharmacology, which may improve data reprodu-
cibility in the ﬁeld. Moreover, our unique approach may serve as
a useful strategy to investigate other classes of molecules with
therapeutic relevance. Such an effort is deemed necessary to allow
a successful transfer of preclinical data to the patient’s bedside.
Methods
General materials. [3H]CP55940 (speciﬁc activity 141.2 Cimmol 1) and
GF-B/GF-C ﬁlters were purchased from Perkin Elmer (Waltham, MA, USA).
Anandamide [arachidonyl-5,6,8,9,11,12,14,15-3H; AEA] (speciﬁc activity
200 Cimmol 1) was purchased from ARC (St Louis, MO, USA). Bicinchoninic
acid (BCA) and BCA protein assay reagent were obtained from Pierce Chemical
Company (Rochford, IL, USA). The PathHunter CHO-K1 CNR1, CNR2 and
mCNR2 b-Arrestin Cell Line (catalogue numbers 93-0959C2, 93-0706C2 and
93-0472C2, respectively) and the PathHunter detection kit (catalogue number
93-0001) were obtained from DiscoveRx. Cell culture plates were purchased from
Sarstedt (catalogue number 83.3902) and 384-well white walled assay plates from
Perkin Elmer (catalogue number 6007680). Cannabinoid reference ligand
CP55940, (Rac)-AM1241, AEA and 2-arachidonoylglycerol (2-AG) were obtained
from Sigma Aldrich (St Louis, MO, USA), JWH133 and Gp-1a from Tocris
Bioscience (Bristol, UK), SR144528, (S)-AM1241 and (R)-AM1241 from Cayman
Chemical Company (Ann Arbor, MI, USA) and HU308, HU910, HU210,
SR141716A, AM630, WIN55212-2 mesylate, and AM251 were obtained from
Hoffman-La Roche (Basel, Switzerland). D9-THC and JWH015 were synthesized
according to published procedures (see below)40–42. Not all compounds were tested
in all labs due to legal restrictions. URB597 and JZL184 were from Cayman
Chemicals (Ann Arbor, MI, USA). Activity-based probes for serine hydrolases
MB064 and TAMRA-FP were synthesized according to literature43, or were bought
from Thermo Fischer Scientiﬁc (Waltham, MA, USA), respectively. All buffers and
solutions were prepared using Millipore water (deionized using a MilliQ A10
Biocel, with a 0.22 mm ﬁlter) and analytical grade reagents and solvents. Buffers are
prepared at room temperature (RT) and stored at 4 C, unless stated otherwise.
Synthetic procedures general remarks. All reactions were performed using oven
or ﬂame-dried glassware and dry solvents. Reagents were purchased from Sigma
Aldrich, Acros and Merck and used without further puriﬁcation unless noted
otherwise. All moisture sensitive reactions were performed under an argon
atmosphere. Traces of water were removed from starting compounds by
co-evaporation with toluene. 1H- and 13C-NMR spectra were recorded on a
Bruker AV 400MHz spectrometer at 400.2 (1H) and 100.6 (13C) MHz. Chemical
shift values are reported in ppm with tetramethylsilane or solvent resonance as the
internal standard (CDCl3 d 7.26 for 1H, d 77.0 for 13C, CD3OD: d 3.31 for 1H).
Data are reported as follows: chemical shifts (d), multiplicity (s¼ singlet, d¼
doublet, dd¼ double doublet, td¼ triple doublet, t¼ triplet, q¼ quartet,
quinted¼ quint, br¼ broad, m¼multiplet), coupling constants J (Hz), and
integration. HPLC puriﬁcation was performed on a preparative LC-MS system
(Agilent 1200serie) with an Agilent 6130 Quadruple MS detector. High-resolution
mass spectra were recorded on a Thermo Scientiﬁc LTQ Orbitrap XL.
Flash chromatography was performed using SiliCycle silica gel type SiliaFlash
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P60 (230–400 mesh). TLC analysis was performed on Merck silica gel
60/Kieselguhr F254, 0.25mm.
Chemical syntheses are described in detail in the Supplementary Methods.
Cell culture and membrane preparation. CHOK1hCB1_bgal, CHOK1hCB2_bgal
and CHOK1mCB2_bgal cells (source: DiscoveRx, Fremont, CA, USA) were
cultured in Ham’s F12 Nutrient Mixture supplemented with 10% fetal calf serum,
1mM glutamine, 50 mgml 1 penicillin, 50 mgml 1 streptomycin, 300mgml 1
hygromycin and 800 mgml 1 geneticin in a humidiﬁed atmosphere at 37 C and
5% CO2. Cells were subcultured twice a week at a ratio of 1:20 on 10-cm ø plates by
trypsinization. For membrane preparation the cells were subcultured 1:10 and
transferred to large 15-cm diameter plates. For membrane preparation, the
cells were detached by scraping them into 5ml phosphate-buffered saline (PBS),
collected and centrifuged at 1,000g for 5min. Pellets derived from 30 plates were
added together and resuspended in 20ml ice-cold buffer (50mM Tris-HCl,
5mM MgCl2, pH 7.4). An UltraThurrax homogenizer was used to homogenize
the cell suspension. Membranes and the cytosolic fraction were separated by
ultracentrifugation (31.000 rpm, with a Ti-70 rotor in a Beckham Coulter
Ultracentrifuge) at 4 C for 20min. The supernatant was discarded and the
pellet was resuspended in 10ml of the same buffer and the homogenization and
centrifugation steps were repeated. Supernatant was discarded and the pellet was
resuspended in 5ml buffer. Aliquots of 200ml were frozen at  80 C until further
use. Protein concentration was determined using the BCA method44.
[3H]CP55940 displacement assay. [3H]CP55940 displacement assays were used
for the determination of afﬁnity (Ki) values of ligands for the cannabinoid CB1 and
CB2 receptors. Membrane aliquots containing 5 mg (CHOK1hCB1_bgal) or 1 mg
(CHOK1hCB2_bgal) of membrane protein in 100 ml assay buffer (50mM Tris-HCl,
5mM MgCl2, 0.1% bovine serum albumin (BSA), pH 7.4) were incubated at
30 C for 1 h, in presence of 3.5 nM [3H]CP55940 (CHOK1hCB1_bgal) or
1.5 nM [3H]CP55940 (CHOK1hCB2_bgal). Non-speciﬁc binding was
determined in the presence of 10 mM AM630 (CHOK1hCB2_bgal) or 10 mM
SR141716A (CHOK1hCB1_bgal). When AEA or 2-AG were used as ligands,
phenylmethylsulphonyl ﬂuoride was used as a serine protease inhibitor. Incubation
was terminated by rapid ﬁltration performed on GF/C ﬁlters (Whatman Interna-
tional, Maidstone, UK), presoaked for 30min with 0.25% PEI, using a Brandel
harvester (Brandel, Gaithersburg, MD, USA). Filter-bound radioactivity was
determined by scintillation spectrometry using a Tri-Carb 2900 TR liquid scintil-
lation counter (Perkin Elmer, Boston, MA, USA). For mouse experiments, brain
(for CB1) and spleen (for CB2) were resuspended in 2mM Tris-EDTA, 320mM
sucrose, 5mM MgCl2 (pH 7.4), then homogenized in a Potter homogenizer and
centrifuged three times at 1000g (10min). The supernatants were centrifuged at
18000g (30min), and the pellets were resuspended in assay buffer (50mMTris-HCl,
2mMTris-EDTA, 3mM MgCl2, pH 7.4). These membrane fractions were used in
rapid ﬁltration assays with 400 pM of [3H]CP55,940. In all binding experiments,
nonspeciﬁc binding was determined in the presence of 1 mM ‘cold’ agonist. When
AEA or 2-AG were used as ligands, the FAAH inhibitor URB597 or the MAGL
inhibitor JZL184, respectively, were included in the assay buffer45. Brain and spleen
tissue was collected from male C57BL/6J mice, 8 months old (supplier: Charles
River Via Indipendenza 11 Calco (Lecco) 23885 Italy), at the Santa Lucia
Foundation within the project: ‘Ruolo del Sistema Endocannabinoide nei Processi
Neurodegenerativi in modelli animali di Alzheime’ by Mauro Maccarrone.
Ethical approval was given by the Ministry of Health, n. 47/2014/PR (deadline 17
November 2019).
[35S]GTPcS assay. G-protein activation by the receptor is measured by the
binding of radiolabelled GTP, [35]GTPgS, to the receptor46. Five micrograms of
homogenized CHOK1CB_bgal membranes in 20 ml assay buffer (50mM Tris-HCl
buffer (pH 7.4), 5mM MgCl2, 150mM NaCl, 1mM EDTA, 0.05% BSA and 1mM
DTT, freshly prepared every day) were pretreated with 5 mg saponin and 1 mM
GDP. To determine the pEC50 and Emax values of cannabinoid reference ligands,
the membranes were incubated with various concentrations of the ligands of
interest. The basal level of GTP binding was measured in untreated membrane
samples, and the maximal level of GTP binding was measured by treatment of the
membranes with 10mM CP55940. All samples were preincubated for 30min at rt,
followed by addition of [35S]GTPgS (0.3 nM). The total value of each sample was
100ml. The samples were incubated for 90min at 25 C on a shaking platform.
Incubations were terminated by rapid vacuum ﬁltration to separate the bound and
free radioligand through Whatman GF/B ﬁlters (Perkin Elmer, Groningen, The
Netherlands) using a Filtermate 96-well harvester (Perkin Elmer, Groningen, The
Netherlands). Filters were subsequently washed ten times with ice-cold wash buffer
containing 50mM Tris HCl, pH 7.4 and 5mMMgCl2. Microscint scintillation ﬂuid
(25 ml, Perkin Elmer, Groningen, The Netherlands) was added to each ﬁlter. After
3 h, the ﬁlter-bound radioactivity was determined by scintillation spectrometry
using a 1450 Microbeta Wallac Trilux scintillation counter (Perkin Elmer).
PathHunter b-arrestin recruitment assay. The assay was performed using
the PathHunter hCB1_bgal, hCB2_bgal, hGPR55_bgal or mCB2_bgal CHOK1
b-arrestin recruitment assay kit (source: DiscoveRx, Fremont, CA, USA), according
to the manufacturer’s protocol47. Brieﬂy, cells were seeded at a density of 5,000 cells
per well of solid white walled 384-well plates (Perkin Elmer, MA, USA) in 20 ml cell
culture medium and incubated overnight (16–18 h) in a humidiﬁed atmosphere at
37 C and 5% CO2. In the endocannabinoid assay, a concentration of 50 mM of
phenylmethylsulphonyl ﬂuoride was freshly added to each well and the cells were
incubated for 30min in a humidiﬁed atmosphere at 37 C and 5% CO2. In the
agonistic assay, the cells were stimulated with 10 mM of each agonist (single point
assay) or 11 increasing concentrations of each agonist and incubated for 90min in
a humidiﬁed atmosphere at 37 C and 5% CO2. In the antagonistic assays, the
cells were exposed to 10mM of each antagonist (single point assay) or 11
increasing concentrations of each antagonist and incubated for 30min in a
humidiﬁed atmosphere at 37 C and 5% CO2, followed by the addition of the
EC80 concentration of CP55940 (25 nM for CHOK1hCB1_bgal and 46 nM
for CHOK1hCB2_bgal). The cells were incubated for 90min in a humidiﬁed
atmosphere at 37 C and 5% CO2. Compounds in DMSO stocksolutions were
added using a HP D300 Digital Dispenser (Tecan, Ma¨nnedorf, Switzerland).
Endocannabinoids 2-AG and anandamide (stocksolutions in acetonitrile) were
added manually. The ﬁnal concentration of organic solvent per assay point
was r0.1%. b-Galactosidase enzyme activity was determined by using the
PathHunter Detection mixture, according to the kit’s protocol47. Detection
mixture, 12ml per well, was added and the plate was incubated for 1 h in the dark
at room temperature. Chemiluminescence, indicated as relative light unit, was
measured on an EnVision multilabel plate reader (Perkin Elmer, MA, USA).
pERK assay. Assays to determine pERK stimulation were performed in HEK cells
stably expressing 3HA-tagged human CB1 receptors and Flp-in HEK cells stably
expressing 1HA-3TCS-tagged hCB2 receptors (3TCS refers to three ‘thrombin
cleavage sites’, which are not relevant for these experiments). HEK-hCB1 cells were
created by transfecting Human Embryonic Kidney 293 (HEK) cells (ATCC
#CRL-1573) with human CB1 (hCB1) chimerized with three hemeagglutinin (HA)
tags at the amino terminus. A single HA tag, three thrombin cleavage sites and a
single ‘L’ residue (for cloning purposes) were chimerized at the N terminus of
hCB2 (Missouri S&T cDNA Resource Center, www.cdna.org, CNR0200000) by
overlap-extension PCR and restriction digest/ligation from DNA oligonucleotides.
The subsequent hCB2 construct was cloned into pcDNA5/FRT (Life Technologies
#V601020) via the NheI and XhoI sites using standard molecular biology techni-
ques and sequence veriﬁed. The human Flp-In-293 cell line (Invitrogen #R750-07)
was stably transfected with the human hCB2 construct for targeted integration into
the FRT site and maintained in 50 mg hygromycin Bml 1 (ref. 48). Cells were
grown in high glucose DMEM, supplemented with 10% fetal bovine serum (FBS)
and were cultured under standard conditions. Brieﬂy, cells from semi-conﬂuent
T75 ﬂasks were seeded in 100ml per well complete medium, in 96-well plates
pre-treated with poly-D-lysine. Approximately 24 h after seeding, cells were
60% conﬂuent and complete medium was removed and replaced with 50 ml per
well serum-free DMEM containing 1mgml 1 BSA, for 18 h to reduce the
pERK background. Drugs were made up in DMEMþ 1mgml 1 BSA at
2 concentrations and cells were stimulated by dispensing 50 ml per well in a
37 C waterbath for exactly 5min. At the conclusion of stimulation, plates were
moved to an ice bed and well contents were rapidly aspirated. Thirty microliters
per well of lysis buffer was immediately dispensed, and plates were placed on
shakers for 10min prior to proceeding to detection. Lysis buffer and detection
reagents were from a PerkinElmer AlphaScreen SureFire pERK (Thr202/Tyr204)
assay kit, and were utilized according to the manufacturer’s instructions. In order
to reduce use of detection reagents, lysates were ﬁrst transferred to 1/2 area, white
96-well plates (PerkinElmer). Detection of hCB1-mediated pERK responses was
performed using the manufacturer’s standard detection protocol, whereas
hCB2 pERK responses were only detected utilizing the high sensitivity detection
protocol. Plates were read on an EnSpire plate reader (PerkinElmer).
GIRK assay. Activation of native GIRK channels in mouse AtT20 neuroblastoma
cells stably transfected with HA-tagged hCB1 or hCB2 receptors (source: cells were
generated by transfecting WT AtT20 with HA-tagged hCB1 or hCB2 receptor. The
cDNA clones for the human CB1 and CB2 receptor with 3N-terminal HA tags
were obtained from the Missouri S&T cDNA Resource Center (www.cdna.org))
was measured as a change in membrane potential using membrane potential-
sensitive dye (blue, Molecular Devices) in a FlexStation three-plate reader49,50.
Brieﬂy, AtT20 cells from an 80–90% conﬂuent 75mm2 ﬂask were resuspended in
L-15 medium supplemented with 1% FBS, 100U penicillin and 100 mg
streptomycin ml 1 and plated in 96-well black-walled plates (90 ml per well).
Cells were incubated overnight in humidiﬁed room air at 37 C. Membrane
potential dye was dissolved in low K HEPES buffered saline (90 ml) and added to
the plate an hour before assay. Fluorescence was measured every 2 s
(kexcitation¼ 530 nm, lemission¼ 565 nm). Assays were carried out at 37 C,
drugs were added in volumes of 20 ml after at least 2min of baseline recording.
Changes in ﬂuorescence were expressed as a percentage of predrug values, after
subtraction of the small changes produced by solvent (0.1% DMSO, 0.1% BSA)
alone. For antagonist experiments, drugs were preincubated for at least 5min
before CP55940 (30 nM) was added. For each drug concentration, the peak change
in ﬂuorescence was normalized to the change produced a maximally effective
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concentration of CP55–940 (1 mM). Data are expressed as the mean±s.e.m. of
N independent experiments, each performed in duplicate.
Mouse cAMP assay. The effect of ligands on the forskolin-stimulated accumu-
lation of cAMP was determined with the LANCE ULTRA cAMP kit (Perkin-Elmer
Life Sciences, Boston, MA, USA) (ref. 51). Brain (for CB1) and spleen (for CB2)
were resuspended in 50mM of Tris-HCl (pH 7.4), then were homogenized in a
Potter homogenizer and centrifuged at 1000g for 10min. The supernatants were
incubated for 30min with 1-methyl-3-isobutylxanthine (IBMX), then forskolin
was added in the presence or absence of ligands. The supernatants were incubated
for 30min in ATP Regeneration Buffer (50mM HEPES, pH 7.4, 10mM
phosphocreatine, 10 unitsml 1 creatine phosphokinase, 10 mM GTP, 200mM
ATP, 10mM MgCl2, 250 mM IBMX), and the reaction was stopped by adding lysis
buffer. Time-resolved ﬂuorescence was measured with a Victor V Multilabel
counter (Perkin-Elmer Life Sciences, Boston, MA, USA). Brain and spleen tissue
was collected from male C57BL/6J mice, 8 months old (supplier: Charles River
Via Indipendenza 11 Calco (Lecco) 23885 Italy), at the Santa Lucia Foundation
within the project: ‘Ruolo del Sistema Endocannabinoide nei Processi
Neurodegenerativi in modelli animali di Alzheime’ by Mauro Maccarrone.
Ethical approval was given by the Ministry of Health, n. 47/2014/PR (deadline 17
November 2019).
Human cAMP assay. cAMP assays were performed with CHO cells stably
expressing human CB1 or human CB2 receptors52 (source: DiscoveRx, Fremont,
CA, USA) using the cAMP-Nano-TRF detection kit (Roche Diagnostics,
Penzberg, Germany). Cells were seeded 17–24 h prior to the experiment at a
density of 3 104 cells per well in a black 96-well plate with ﬂat clearbottom
(Corning, Wiesbaden, Germany) and incubated in 5% CO2 at 37 C in a humidiﬁed
incubator. The growth medium was exchanged with Krebs Ringer bicarbonate
buffer with 1mmol l 1 3-isobutyl-1-methylxanthine (IBMX), 0.1% fatty acid-free
BSA and incubated at 30 C for 60min. Agonist was added to a ﬁnal assay volume
of 100 ml and the mixture was incubated for 30min at 30 C. The assay was stopped
by the addition of 50ml 3 lysis reagent and shaken for 2 h at room temperature.
The time-resolved energy transfer was measured using an LF502 Nanoscan
FLT (IOM, Berlin, Germany), equipped with a laser as excitation source. cAMP
content was determined from the function of a standard curve spanning from
10 to 0.13 nmol l 1 cAMP.
Data analysis of functional assays. All experimental data were analysed
using the nonlinear regression curve ﬁtting program GraphPad Prism 6.0
(GraphPad Software, Inc., San Diego, CA, USA). From displacement assays,
pIC50 values were obtained by non-linear regression analysis of the displacement
curves. The obtained pIC50 values were converted into pKi values using the Cheng
Prusoff equation to determine the afﬁnity of the ligands (KD: 0.33 (CB2R),
0.10 (CB1R)) (ref. 53). b-Arrestin recruitment and GTPgS curves were analysed by
the nonlinear regression option ‘log (agonist or inhibitor) versus response-variable
slope’ to obtain potency, inhibitory potency or efﬁcacy values of agonists and
inverse agonists (EC50, IC50 or Emax, respectively). Basal activity of the cells is set at
0%. For the b-arrestin recruitment assay, all data points were corrected for any
background (for example, background luminescence). For the analysis of
antagonists measured in competition with CP55940, the nonlinear regression
option ‘log (inhibitor) versus response’ was chosen. The response of agonists per
sample is normalized to the effect of 10 mM CP55940 and the response of
antagonists is normalized to effect of the EC80 of CP55940. For the GTPgS assay,
agonistic effect is normalized to the effect of 10 mM CP55940. Data shown are the
mean±s.e.m. of at least three independent experiments, each performed in
duplicate, unless stated otherwise.
Data analysis for bias calculations. The data used for the operation analysis
was the data of at least three independent experiments on each assay, all nor-
malized to the effect of 10 mM CP55940. The analysis used was based on van der
Westhuizen et al.30 For more details about the discovery of the operational model
and its mathematical background, see Black and Leff and Kenakin et al.31,54,55
See Supplementary Methods for a full step-by-step procedure.
AEA reuptake inhibition in HaCaT cells. The uptake of [3H]AEA was measured
in intact HaCaT cells (a kind gift of Prof N.E. Fusenig (German Cancer Research
Center, Heidelberg, Germany), that were incubated in PBS at 37 C with a
mixture of AEA [arachidonyl-5,6,8,9,11,12,14,15-3H] (200 Cimmol 1) and cold
AEA (at a ﬁnal concentration of 400 nM) for 15min (ref. 56). Control experiments
were carried out also at 4 C and in the presence of the selective AEA reuptake
inhibitor OMDM-1 (10 mM). The effect of different ligands on AEA reuptake was
tested by adding each substance directly to the incubation medium.
AEA reuptake inhibition in HMC-1 cells and U937 cells. Compound screening
and IC50 determinations for AEA cellular uptake in U937 cells and HMC-1
cells (source: U937 cells were purchased from ATCC, Manassas, VA, USA, HMC-1
cells were a gift of Prof S. Sta¨nder, University of Mu¨nster with the permission of the
Mayo Foundation, USA) was performed in 96-well format using AquaSil silanized
glass vials (Chromacol 1.1-MTV) (refs 32,57). First, required amounts of U937 cells
were centrifuged at 100g for 5min and resuspended in RPMI (37 C) to a ﬁnal
concentration of 2 106 cellsml 1. Then, 250ml of cell suspension (0.5 106 cells
per sample) were transferred into the glass vials. After addition of 5 ml vehicle
(DMSO) or test compounds dissolved in DMSO at indicated ﬁnal concentrations
the cells were incubated at 37 C for 15min. After pre-incubation a mixture of
0.5 nM [ethanolamine-1-3H]-AEA, (60 Cimmol 1) and 99.5 nM of cold
AEA (ﬁnal 100 nM) was added and the samples were incubated at 37 C
for another 15min. In the FAAH-deﬁcient HMC-1 cells, [arachidonoyl-
5,6,8,9,11,12,14,15-3H]-AEA (200Cimmol 1) was used in order to achieve a
better signal-to-background ratio, due to the lower rate of AEA uptake.
The reaction was stopped by rapid ﬁltration over UniFilter-96 GF/C ﬁlters
(Perkin Elmer) pre-soaked with PBS 1% BSA. Cells on ﬁlters were washed three
times with 100 ml ice-cold PBS buffer containing 1% fatty acid free BSA. After
drying, 45ml MicroScint 20 scintillation cocktail (Perkin Elmer, Waltham, MA,
USA) was added to the wells and the plate was sealed. Radioactivity was measured
by liquid scintillation counting on a Perkin Elmer Wallac Trilux MicroBeta
1450 during 2min. Samples were measured in triplicates in n¼ 3 independent
experiments except the screening run (n¼ 1). Each run was validated using the
positive controls OMDM-2 and UCM707 at a concentration of 10 mM reaching
59.7±6.6% (n¼ 7) and 71.5±8.0% (n¼ 7) respectively.
NAPE-PLD inhibition. Full length human cDNA NAPE-PLD was obtained
from Natsuo Ueda58 and cloned into mammalian expression vector pcDNA3.1,
containing a C-terminal Flag-tag and genes for ampicillin and neomycin resistance.
All plasmids were grown in XL-10 Z-competent cells and prepped (Maxi Prep,
Qiagen). Sequence analysis for the conﬁrmation of the sequences was performed at
the Leiden Genome Technology Centre.
HEK293T cells (source: Dutch Cancer Institute) were cultured at 37 C and
7% CO2 in DMEM with glutamax, penicillin (100 mgml 1), streptomycin
(100 mgml 1) and 10% New Born Calf Serum iron supplemented (Hyclone
SH30072.03). Cells were passaged twice a week to appropriate conﬂuence.
Twenty-four hours before transfection 107 cells were seeded on a 15 cm dish. Two
hours before transfection, the medium was refreshed. Transfection is performed
with PEI in a ratio of 3:1 with human NAPE-PLD or Mock pcDNA3.1Neo, 20 mg
per dish. Medium is refreshed after 24 h and cells are harvested after 72 h. Cell
suspensions are centrifuged at 1,000g for 10min, supernatant removed and pellets
frozen at  80 C until further use.
Cell pellets are re-suspended in lysis buffer 1: 20mM Hepes, 2mM DTT, 0.25M
sucrose, 1mM MgCl2, 2.5Uml 1 benzonase and incubated 30min on ice. The
cytosolic fraction (supernatant) is separated from the membranes by ultra-
centrifugation (32,000 rpm for 30min 100,000g). The pellet is resuspended in
buffer 2: 20mM Hepes, 2mM DTT (membrane fraction). All samples are stored at
 80 C. Enzyme concentrations are determined using a Bradford assay59.
The membrane protein fraction from transient overexpression of NAPE-PLD in
HEK293T cells was diluted to 0.4mgml 1 in assay buffer: 50mM Tris-HCl
(pH 7.5), 0.02% Triton X-100, 150mM NaCl (ref. 60). The substrate PED6
(Invitrogen) 10mM stock was consecutively diluted in DMSO (25 ) and in assay
buffer (10 ). Relevant concentrations of compounds are prepared in DMSO.
The assay is performed in a dark Greiner 96-well plate, end volume 100 ml.
The compound or DMSO is incubated with membrane protein lysate
(ﬁnal concentration 0.04mgml 1) for 30min at 37 C. A sample without
membrane protein lysate is incorporated for background subtraction. Then,
substrate is added (ﬁnal concentration 1 mM) and the measurement is started
immediately on a TECAN inﬁnite M1000 pro at 37 C (excitation 485 nm, emission
535 nm), scanning every 2min for 1 h.
Cell culture and membrane preparation for DAGL, MAGL assay. Cell culture
and membrane preparation were performed as previously described43. HEK293T
cells (source: Dutch Cancer Institute) were grown in DMEM with stable glutamine
and phenolred (PAA), 10% New Born Calf serum, penicillin and streptomycin.
Cells were passaged every 2–3 days by resuspending in medium and seeding them
to appropriate conﬂuence. Membranes were prepared from transiently transfected
HEK293T cells. One day prior to transfection 107 cells were seeded in a 15 cm petri
dish. Cells were transfected by the addition of a 3:1 mixture of polyethyleneimine
(60 mg) and plasmid DNA (20mg) in 2ml serum-free medium. The medium was
refreshed after 24 h, and after 72 h the cells were harvested by suspending them in
20ml medium. The suspension was centrifuged for 10min at 1000 rpm, and the
supernatant was removed. The cell pellet was stored at  80 C until use. Cell
pellets were thawed on ice and suspended in lysis buffer A (20mM HEPES, 2mM
DTT, 0.25M sucrose, 1mM MgCl2, 25U ml 1 Benzonase). The suspension was
homogenized by polytrone (3 7 s) and incubated for 30min on ice. The
suspension was subjected to ultracentrifugation (100,000 g, 30min, 4 C,
Beckman Coulter, Type Ti70 rotor) to yield the cytosolic fraction in the
supernatant and the membrane fraction as a pellet. The pellet was resuspended in
lysis buffer B (20mM HEPES, 2mM DTT). The protein concentration was
determined with Quick Start Bradford assay (Biorad). The protein fractions were
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13958
10 NATURE COMMUNICATIONS | 8:13958 | DOI: 10.1038/ncomms13958 | www.nature.com/naturecommunications
diluted to a total protein concentration of 1mgml 1 and stored in small aliquots
at  80 C until use.
Biochemical DAGLa activity assay. hDAGL-a activity was measured by the
extent of the hydrolysis of para-nitrophenylbutyrate (PNP-butyrate) by membrane
preparations from HEK293T cells (source: Dutch Cancer Institute) transiently
transfected with hDAGL-a (ref. 43). Percentage of inhibition of reference ligands
was determined in comparison with an untreated control. Reactions were
performed in 50mM pH 7.2 HEPES buffer with 0.05 mg ml 1 ﬁnal protein
concentration hDAGL-a transfected protein.
Biochemical MAGL activity assay. MAGL activity was measured by the extent
of the production of glycerol from 2-AG hydrolysis by MAGL-overexpressing
membrane preparations from transiently transfected HEK293T cells
(source: Dutch Cancer Institute)61. Percentage of inhibition of reference ligands
was determined in comparison with an untreated control. Standard assay
conditions are as follows: 0.2Uml 1 glycerol kinase (GK), glycerol-3-phosphate
oxidase (GPO) and horseradish peroxidase (HRP), 0.125mM ATP, 10 mM
AmplifuRed, 5% DMSO, 25 mM 2-AG and 0.5% acetonitrile in a total volume of
200ml. Fluorescence was measured in 5min intervals for 60min.
FAAH activity. FAAH activity was assessed using U937 cell homogenate
(source: U937 cells were purchased from ATCC, Manassas, VA, USA). Tested
compounds (at the concentrations of 1 and 5 mM) or solvent (r1% of the ﬁnal
volume) were pre-incubated at 37 C for 30min with 100 mg of cell homogenate
diluted in assay buffer (10mM Tris-HCl and 1mM EDTA, pH 7.6 and 1% w/v
fatty acid-free BSA). Successively, a mixture of 99.5 nMnM of AEA and 0.5 nM of
[ethanolamine-1-3H]-AEA (40–60Cimmol 1) was added to the homogenate
(ﬁnal concentration of 100 nM) and incubated for 10min at 37 C under shaking.
After the incubation time, 2 volumes of an ice-cold methanol: chloroform mixture
1:1 (v/v) were added to each sample, vigorously vortexed and centrifuged at
10,000g for 10min at 4 C to separate aqueous and organic phases. The aqueous
phases were collected and the radioactivity associated with the hydrolysis product
[3H]-ethanolamine was measured after addition of 3ml of scintillation cocktail
using the Tri-Carb 2100 TR scintillation counter. Data were collected from three
independent experiments performed in triplicate and results were expressed as
FAAH activity, relative to that in vehicle-treated samples (¼ 100%).
COX2 activity. The COX2 activity was assessed using a COX ﬂuorescent inhibitor
screening assay kit from Cayman chemicals. The assay was performed in a ﬁnal
volume of 50 ml in black 384-well non-binding microplates. Tested compounds
(at the screening concentration of 5 mM, 2.5 ml) or solvent were incubated for
15min at 37 C with the following solution: 37.5 ml of assay buffer (Tris-HCl,
100mM, pH¼ 8), 2.5 ml of heme (ﬁnal concentration of 1 mM), 2.5 ml of COX-2
enzyme and 2.5 ml of 10-acetyl-3,7-dihydroxyphenoxazine (ADHP) ﬂuorometric
substrate (ﬁnal concentration of 30 mM). The reaction was started by addition of
arachidonic acid (AA) or 2-AG (2.5 ml, ﬁnal concentration of 10 mM). Fluorescence
signals were measured after 5min of incubation with a TECAN FARCyte Ultra
(Ex. 535 nm, Em. 580 nm). The COX inhibitor DuP-697 (1 mM) was used as a
positive control. Spontaneous non-enzymatic cleavage of ADHP was quantiﬁed in
samples where COX2 was replaced by assay buffer. The non-speciﬁc value was then
subtracted from the measured ﬂuorescence. Data were collected from three inde-
pendent experiments performed in triplicate and results were expressed as
COX2 activity, relative to that in vehicle-treated samples (¼ 100%).
ABHD6 and ABHD12 activity. HEK293T cells were obtained from American
Type Culture Collection (ATCC, Manassas, VA, USA). Lipofectamine 2000 was
obtained from Life Technologies (Carlsbad, CA, USA) and geneticin from Invi-
voGen. Cell culture medium, FBS, and cell culture supplements were from Invi-
trogen (Carlsbad, CA, USA). pCMV6-AC-hABHD6 and pCMV6-XL4-hABHD12
were a kind gift from Prof Jarmo T. Laitinen. hABHD12 sequence was subse-
quently inserted in a pcDNA3.1 plasmid in order to generate a stable cell line. The
effect of CB2R ligands on ABHD6 and ABHD12 hydrolytic activity was determined
using cell homogenate from hABHD6 and hABHD12 overexpressing HEK293T
cells (40 mg total protein per condition). Samples were pre-incubated with the
compounds (10mM in the screening assay and concentrations in the range
1 nM—50 mM for the dose-response curves) in Tris 1mM, EDTA 10mM
(pH¼ 7.6) buffer containing 0.1%(w/v) BSA. DMSO was used as vehicle control
and WWL70 10mM or THL 20 mM as positive controls. [3H]-2-OG (10 mM ﬁnal
concentration) was added and after incubation of 5min at 37 C, the reaction was
stopped by the addition of 400 ml of ice-cold CHCl3:MeOH (1:1). The samples were
vortex and centrifuged (16,100g 10min 4 C). Aliquots (200 ml) of the aqueous
phase were assayed for tritium content by liquid scintillation spectroscopy. The
values obtained for each measurement were corrected for non-speciﬁc hydrolysis
(non-ABHD6 mediated) by subtracting the signal obtained in the hydrolysis of
[3H]- 2-OG by non-transfected HEK293T.
Activity-based protein proﬁling in mouse brain tissue. Mouse tissue was
isolated according to guidelines approved by the ethical committee of Leiden
University (DEC#13191) (ref. 43). Animal care, tissue isolation and the following
experimental procedures was all performed at the lab of Mario van der Stelt, Leiden
University. Mouse tissues were homogenized in pH 7.2 lysis buffer (20mM Hepes,
2mM DTT, 1mM MgCl2, 25Uml 1 Benzonase) and incubated for 5min on ice,
followed by low speed spin (2,500g, 3min, 4 C) to remove debris. The suspension
was subjected to ultracentrifugation (100,000g, 45min, 4 C, Beckman Coulter,
Type Ti70 rotor) to separate the cytosolic fraction from the membrane fraction.
The pellet was resuspended in storage buffer (20mM Hepes, 2mM DTT). The total
protein concentration was determined with Quick Start Bradford assay (Biorad) or
Qubit protein assay (Invitrogen). Tissue proteome (2.5mgml 1) was incubated
with vehicle (DMSO) or inhibitor in 0.5 ml DMSO (10 mM ﬁnal concentration)
for 30min at rt, and subsequently incubated with broad spectrum ABPs MB064
(250 nM ﬁnal concentration) or TAMRA-FP (500 nM ﬁnal concentration)
for 15min at rt (ref. 43). The reactions were quenched with 10 ml standard
3 SDS-PAGE sample buffer. The samples were directly loaded (7 ml¼B12mg)
and resolved on SDS page gel (10% acrylamide). The gels were visualized and
scanned with a Bio-Rad Universal Hood III (Bio-Rad Laboratories B.V.) using
Cy3/TAMRA settings (excitation wavelength 532 nm, emission wavelength
580 nm).
Off-target activity on TRP channels. HEK293 (human embryonic kidney) cells
stably over-expressing recombinant human TRPV1 or rat TRPA1, TRPV2, TRPV3,
TRPV4 or TRPM8 (source: human embryonic kidney cells were purchased by
DSMZ (Germany), TRPV1-HEK-293 cells were a kind gift from John Davis,
GlaxoSmithKline, Harlow, UK, the plasmid for TRPV2, as well as TRPV3-HEK-
293 and TRPV4-HEK-293 were a kind gift from HB Bradshaw Indiana University,
the plasmid containing TRPA1 was a kind gift from Sven-Eric Jordt then at
Department of Cellular and Molecular Pharmacology University of California,
San Francisco, California, USA and now at Department of Anesthesiology, Duke
University School of Medicine, Durham, NC, USA, TRPM8-HEK-293 was a gift
from Mario van der Stelt) were grown on 100mm diameter Petri dishes as
mono-layers in minimum essential medium supplemented with non-essential
amino acids, 10% FBS, 2mM glutamine, and maintained at 5% CO2 at
37 C. Quantitative real-time analysis was carried out to measure TRP gene
over-expression in transfected-cells (data not shown). On the day of the experi-
ment, cells were loaded with the methyl ester Fluo-4 AM in minimum essential
medium (4 mM in DMSO containing 0.02% Pluronic F-127, Invitrogen), kept
in the dark at room temperature for 1 h, washed twice with Tyrode’s buffer
(145mM NaCl, 2.5mM KCl, 1.5mM CaCl2, 1.2mM MgCl2, 10mM D-glucose,
and 10mM HEPES, pH 7.4), resuspended in the same buffer and transferred
(about 100,000 cells) to the quartz cuvette of the spectroﬂuorimeter (Perkin-Elmer
LS50B equipped with PTP-1 Fluorescence Peltier System; PerkinElmer Life and
Analytical Sciences, Waltham, MA, USA) under continuous stirring. The effects on
intracellular Ca2þ concentration ([Ca2þ ]i) before and after the addition of various
concentrations of test compounds was measured by cell ﬂuorescence (lEX¼ 488
nm, lEM¼ 516 nm) at 25 C. The effects of compounds were normalized against
the response to ionomycin (4 mM) in each experiment. The increases in ﬂuores-
cence in wild-type HEK293 cells (that is, not transfected with any construct) were
used as baseline and subtracted from the values obtained from transfected cells.
Efﬁcacy was deﬁned as the maximum response elicited by the compounds tested
and was determined by comparing their effect with the analogous effect observed
with 4 mM ionomycin (Cayman), while the potency of the compounds (EC50) was
determined as the concentration required to produce half-maximal increases in
[Ca2þ ]i. Curve ﬁtting (sigmoidal dose-response variable slope) and parameter
estimation were performed with GraphPad Prism (GraphPad Software Inc., San
Diego, CA, USA).
Antagonist/desensitizing behaviour was evaluated by adding the test
compounds in the quartz cuvette 5min before stimulation of cells with agonists. In
the case of human TRPV1-expressing HEK293 cells the agonist used was capsaicin
(0.1 mM, in the case of SR141716A 10 nM was also used), which was able of
elevating intracellular Ca2þ with a potency of EC50¼ 5.3±0.4 nM and
efﬁcacy¼ 78.6±0.6%.
For TRPV2, the rat TRPV2-HEK293 cells exhibited a sharp increase in [Ca2þ ]i
upon application of lysophosphatidylcholine (LPC) 3 mM. The concentration for
half-maximal activation was 3.40±0.02mM and efﬁcacy was 91.7±0.5%.
In the case of TRPV3, rat TRPV3-expressing HEK-293 cells were ﬁrst sensitized
with the non-selective agonist 2-aminoethoxydiphenyl borate (100 mM).
Antagonist/desensitizing behaviour was evaluated against thymol (100 mM), which
showed an efﬁcacy of 34.7±0.2% and a potency of EC50¼ 84.1±1.6 mM.
In the case of rat TRPV4-expressing HEK-293 cells the agonist used was
4a-phorbol 12,13-didecanoate (4a-PDD) (1mM), which was able of elevating
intracellular Ca2þ with a potency of EC50¼ 0.46±0.07 mM, and an efﬁcacy of
51.9±1.7%.
In the case of rat TRPM8-expressing HEK-293 cells, antagonist/desensitizing
behaviour was evaluated against icilin at 0.25 mM and 0.10 mM. For icilin, efﬁcacy
was 75.1±1.1 and potency EC50¼ 0.11±0.01mM.
In the case of HEK-293 cells stably over-expressing recombinant rat TRPA1, the
effects of TRPA1 agonists are expressed as a percentage of the effect obtained with
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100mM allyl isothiocyanate, which showed a potency of EC50¼ 1.41±0.04 mM and
an efﬁcacy of 65.9±0.5.
The effect on [Ca2þ ]i exerted by agonist alone was taken as 100%. Data are
expressed as the concentration exerting a half-maximal inhibition of agonist-
induced [Ca2þ ]i elevation (IC50), which was calculated again using GraphPad. All
determinations were performed at least in triplicate. Statistical analysis of the data
was performed by analysis of variance at each point using ANOVA followed by the
Bonferroni’s test.
CEREP panel. Pharmacological proﬁles of the test compounds were generated.
Data shown give the percentage of inhibition for binding assays and the percentage
of inhibition for enzyme and cell-based assays at a test concentration of 10 mM. The
assays were performed at CEREP according to standard procedures described
under http://www.cerep.fr/cerep/users/index.asp. For the ﬁrst compounds being
evaluated (WIN55212-2, CP55940, SR141716A, JWH133, HU308, Gp-1a and
HU910) standard proﬁles as suggested by CEREP were applied. For the other
compounds reduced panels concentrating on most predictive antitargets and
omitting rarely hit sites were used.
Microsomal clearance. For human or mice, pooled commercially available
microsome preparations from liver tissues are used (source: pooled human
microsomes (BD UltraPool HLM 150,Lot 38289) and pooled male mouse micro-
somes (C57BL/6J, Lot 4339006) were purchased from Corning Incorporated
(Woburn, USA))62. For human, ultra-pooled (150 mixed gender donors) liver
microsomes are purchased to account for the biological variance in vivo. For the
microsome incubations, 96 deep well plates are applied, which are incubated at
37 C on a TECAN (Tecan Group Ltd, Switzerland) equipped with Te-Shake
shakers and a warming device (Tecan Group Ltd, Switzerland). The incubation
buffer is 0.1M phosphate buffer at pH 7.4. The NADPH regenerating system
consists of 30mM glucose-6-phosphate disodium salt hydrate; 10mM NADP;
30mM MgCl2 6 H2O and 5mgml 1 glucose-6-phosphate dehydrogenase
(Roche Diagnostics) in 0.1M potassium phosphate buffer pH 7.4.
Incubations of a test compound at 1 mM in microsome incubations of
0.5mgml 1 plus cofactor NADPH are performed in 96-well plates at 37 C.
After 1, 3, 6, 9, 15, 25, 35 and 45min 40 ml incubation solutions are transferred and
quenched with 3:1 (v/v) acetonitrile containing internal standards. Samples are
then cooled and centrifuged before analysis by LC-MS/MS.
Log peak area ratios (test compound peak area/internal standard peak area) are
plotted against incubation time using a linear ﬁt. The calculated slope is used to
determine the intrinsic clearance: Clint (ml min 1 per mg protein)¼  slope
(min 1) 1,000/[protein concentration (mgml) 1]. Data are obtained from
single experiments measured with multiple time-points.
Hepatocyte clearance. For animals, hepatocyte suspension cultures are either
freshly prepared by liver perfusion studies or prepared from cryopreserved
hepatocyte batches63. For human, commercially available, pooled (5–20 donors),
cryopreserved human hepatocytes from non-transplantable liver tissues are mainly
used (source: primary, pooled human cryopreserved hepatocytes (Lot ECO) from
nontransplantable liver tissues and pooled C57BL6 mouse hepatocytes (Lot PJJ)
were purchased from BioreclamationIVT (NY, USA)). For the suspension cultures,
Nunc U96 PP-0.5ml (Nunc Natural, 267245) plates are used, which are incubated
in a Thermo Forma incubator from Fischer Scientiﬁc (Wohlen, Switzerland)
equipped with shakers from Variomag Teleshake shakers (Sterico, Wangen,
Switzerland) for maintaining cell dispersion. The cell culture medium is William’s
media supplemented with Glutamine, antibiotics, insulin, dexamethasone and 10%
FCS.
Incubations of a test compound at 1 mM test concentration in suspension
cultures of 1 Mio cellsml 1 (B1mgml 1 protein concentration) are performed
in 96-well plates and shaked at 900 rpm for up to 2 h in a 5% CO2 atmosphere and
37 C. After 3, 6, 10, 20, 40, 60 and 120min 100 ml cell suspension in each well is
quenched with 200 ml methanol containing an internal standard. Samples are then
cooled and centrifuged before analysis by LC-MS/MS.
Log peak area ratios (test compound peak area/internal standard peak area) or
concentrations are plotted against incubation time and a linear ﬁt made to the data
with emphasis upon the initial rate of compound disappearance. The slope of the ﬁt
is then used to calculate the intrinsic clearance: Clint (ml min 1 1 1 106
cells)¼  slope (min 1) 1,000/[1 106 cells]. Data are obtained from single
experiments measured with multiple time-points.
Plasma protein binding. Pooled and frozen plasma from selected species were
obtained from commercial suppliers (The pooled and frozen plasma from human
(HMPLEDTA, Lot BRH1060627) and mouse (MSEPLEDTA3-C57, Lot
MSE196204) were obtained from BioreclamationIVT (NY, USA).)64,65. The
Teﬂon equilibrium dialysis plate (96-well, 150ml, half-cell capacity) and cellulose
membranes (12–14 kDa molecular weight cutoff) were purchased from
HT-Dialysis (Gales Ferry, CT, USA). Both biological matrix and phosphate buffer
pH are adjusted to 7.4 on the day of the experiment. The reference substance is
diazepam.
The determination of unbound compound is performed using a 96-well
format equilibrium dialysis device with a molecular weight cut-off membrane of
12-14 kDa. The equilibrium dialysis device itself is made of Teﬂon to minimize
non-speciﬁc binding of the test substance. Compounds are tested in cassettes of
2–5 with an initial total concentration of 1000 nM, one of the cassette compound
being the positive control diazepam.
Equal volumes of matrix samples containing substances and blank dialysis
buffer (Soerensen buffer at pH 7.4) are loaded into the opposite compartments of
each well. The dialysis block is sealed and kept for 5 h at a temperature of 37 C and
5% CO2 environment in an incubator. After this time, equilibrium will have been
reached for the majority of small molecule compounds with a molecular weight of
o600. The seal is then removed and matrix and buffer from each dialysis is
prepared for analysis by LC-MS/MS. All protein binding determinations are
performed in triplicates. The integrity of membranes is tested in the HTDialysis
device by determining the unbound fraction values for the positive control
diazepam in each well.
At equilibrium, the unbound drug concentration in the biological matrix
compartment of the equilibrium dialysis apparatus is the same as the concentration
of the compound in the buffer compartment. Thus, the percent unbound fraction
(fu) can be calculated by determining the compound concentrations in the buffer
and matrix compartments after dialysis as follows: %fu¼ 100 buffer conc after
dialysis/matrix conc after dialysis. The device recovery is checked by measuring the
compound concentrations in the matrix before dialysis and calculating the percent
recovery (mass balance). The recovery must be within 80-120% for data
acceptance.
P-glycoprotein binding. P-glycoprotein (permeability-glycoprotein, abbreviated
as ‘P-gp’ also known as multidrug resistance protein 1 (MDR1)) is the most studied
and best characterized drug transporter. The P-gp assay evaluates the ability of test
compounds to be transported transcellularly as a P-gp substrate66. The assay uses
transfected LLC-PK1 cells (porcine kidney epithelial cells, obtained from the
Netherlands Cancer Institute) expressing human or mouse P-gp, cultured on
96-well semi-permeable ﬁlter membrane plates, where they form a polarized
monolayer with tight junctions, and act as a barrier between apical and basolateral
compartments. P-gp is expressed in the apical-facing membrane of the monolayer
(tightness conﬁrmed using Lucifer yellow). For substrate testing the assay
determines the unidirectional permeability (Papp) of a test compound by
separately dosing to the apical (for A4B Papp) and basolateral (for B4A Papp)
sides of the cell monolayer (that is, donor compartments) and measuring the
movement of the compound into the respective receiver compartments over a
3 h incubation at 37 C. The effect of P-gp is measured by expressing the efﬂux
ratio (ER) of the unidirectional A4B and B4A Papp values. The mean
permeability (A4B and B4A Papp) is determined in the absence of P-gp via
addition of the selective inhibitor zosuquidar at a concentration of 1 mM. The
ER and mean Papp are then used to categorize compound properties regarding
their degree of efﬂux and permeability.
PAMPA. PAMPA (Parallel Artiﬁcial Membrane Permeability Assay) is a method
which determines the permeability of substances from a donor compartment,
through a lipid-infused artiﬁcial membrane into an acceptor compartment. Read-
out is a permeation coefﬁcient Peff drug as well as test compound concentrations in
donor, membrane and acceptor compartments67.
A 96-well microtiter plate completely ﬁlled with aqueous buffer solutions
(pH 7.4/ 6.5) is covered with a microtiter ﬁlterplate like a sandwich construction.
The hydrophobic ﬁlter material (Durapore/Millipore; pore size 0.22–0.45 mm) of
the ﬁrst 48 wells (sample) of the ﬁlterplate is impregnated with a 1–20% solution of
lecithin in an organic solvent (dodecane, hexadecane, 1,9-decadiene). The ﬁlter
surface of the remaining 48 wells (reference) is wetted with a small volume (4–5 ml)
of a 50% (v/v) methanol/buffer solution. Transport studies were started by the
transfer of 100–200 ml of a 250 or 500 mM stock solution on top of the ﬁlterplate in
the sample and in the reference section, respectively. In general 0.05M TRIS,
pH 7.4, or 0.05M phosphate, pH 6.5, buffers were used. The maximum DMSO
content of the stock solutions was 5%.
Kinetic solubility. The solubility of a test compound in phosphate buffer at pH 6.5
from evaporated DMSO compound stock solution is measured over time, resulting
in the kinetic solubility of the compounds.
Triad assay in mice using cumulative dosing procedure. These animal experi-
ments were performed in the lab of Prof Lichtman, Virginia Commonwealth
University. Male C57BL6/J mice were purchased from Jackson Laboratories
(Bar Harbor, ME, USA) and were between 10 and 12 weeks of age during treat-
ment. The animal protocol for the triad assay was approved by the Institutional
Animal Care and Use Committee at Virginia Commonwealth University in
accordance with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals68. After testing was completed, all mice were humanely
euthanized via CO2 asphyxia, followed by rapid cervical dislocation. All studies
involving animals are reported in accordance with the ARRIVE guidelines for
reporting experiments involving animals69.
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Each subject (23–29 g) was assessed for catalepsy, antinociception and
hypothermia as a measure of in vivo CB1 receptor activity using a cumulative
dosing procedure to examine the dose-effect relationship of each drug tested70.
Before dosing, baseline measurements of catalepsy, antinociception and
hypothermia were taken and mice were injected with the vehicle consisting of
1 part ethanol, 1 part Alkumus-620 Emulphor and 18 parts 0.9% saline. At 30min
after injection, mice were again assessed for catalepsy, antinociception and
hypothermia, which required 10min to test all mice. This process was repeated
using cumulative doses of HU210 (0.03–3.0mg kg 1), HU308 (1–100mg kg 1),
HU910 (1–100mg kg 1), and JWH133 (1–100mg kg 1) in half log increments,
such that mice were injected every 40min and tested 30min after each injection
until the end of the test session. Separate groups of mice (n¼ 8) were utilized for
each of the four drugs. All injections were given via the intraperitoneal (i.p.) route
of administration in an injection volume of 10 ml per 1 g body mass.
For the antagonism experiments, mice from cumulative dosing experiments for
HU308, HU910 and JWH133 were utilized again (after a 1 week washout period),
to assess whether HU910 (30mg kg 1) would antagonize the cannabimimetic
effects of an ED84 dose of HU210. For comparison, a separate experiment was
conducted using the CB1 receptor antagonist/inverse agonist rimonabant
(3mg kg 1). Mice were evenly distributed with respect to drug history across
treatment groups in each of these two experiments assessing antagonism. Baseline
responses were assessed prior to injections. Subjects in each experiment received an
i.p. injection of either vehicle or the appropriate receptor antagonist at 0min, a
second i.p. injection of vehicle or HU210 (1.7mg kg 1, which reﬂected the
approximate ED84 value in producing antinociception and hypothermia) at 40min.
Mice were tested for catalepsy, antinociception and hypothermia 30min after each
injection.
Data from the dose-response studies were analysed via one-way repeated
measures ANOVA followed by Dunnett’s post hoc test (versus vehicle). ED50 and
ED84 values were determined via linear regression for drugs eliciting maximal
effects for a given endpoint. Data from the antagonism experiments were analysed
via two-way ANOVA in which the factors were antagonist versus vehicle and
HU210 versus vehicle. Post hoc analysis was conducted using the Holm-Sidak test.
P values ofo0.05 were deﬁned as signiﬁcant.
In vivo pharmacokinetic studies. Male C57BL/6J mice were obtained from CRL-F
(Charles River, France), male Wistar rats were supplied by RCC Fu¨llinsdorf and
male C57BL/6JRj mice were from Janvier (France). Animals were up to 12 weeks of
age. All animal studies in this section were performed at Hoffmann-La Roche and
approved by the Bundesamt fu¨r Lebensmittelsicherheit und Veterina¨rwesen (BLV)
der Schweizerischen Eidgenossenschaft. Test compounds were formulated
according to respective protocols either by dissolution (i.v.) or in a glass potter until
homogeneity was achieved (p.o) (formulations for p.o. administration: JWH133
and HU308 were formulated as a microsuspension in Gelatine/NaCl (7.5/0.62%) in
water and HU910 was formulated as a solution in ethanol/cremophor EL/NaCl
0.9% (5/5/90%)). Formulations were injected i.v. using a 30G needle in the lateral
tail vein of mice using a volume of 50 ml in the dose indicated. For p.o. applications
animals were gavaged using a volume of 100 ml in the dose indicated. At the
following time points blood was drawn into EDTA: 0.08, 0.25, 0.5, 1, 2, 4, 7 h
(for p.o. the ﬁrst time point was omitted). Six animals were used for each
compound in vivo experiment. Animals were distributed randomly over the time
course and at each time point, a volume of 100 ml of blood was taken. Quantitative
plasma measurement of the compound was performed by LC-MS/MS analysis.
Pharmacokinetic analysis was performed using Phoenix WinNonlin 6.4 software
using a non-compartmental approach consistent with the route of administration.
For assessment of the exposure Cmax, Tmax and AUC were determined from the
serum concentration proﬁles. Parameters (CL, versus, T1/2) were estimated
using nominal sampling times relative to the start of each administration.
CO was extrapolated from the ﬁrst concentration measured following intravenous
administration.
Data availability. The data that support the ﬁndings of this study are included in
the published article and its Supplementary Information, or are available from the
corresponding author on reasonable request.
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